Ivana Ritter

Statistics

Publications

Citations

694

H-Index

Active since

2020

Affiliations

Boehringer Ingelheim (Germany)(Current)

Universitätsklinikum Würzburg

University of Mississippi Medical Center

Oslo University Hospital

Boehringer Ingelheim (United States)

Ivana Ritter is an author at Boehringer Ingelheim (Germany) specializing in pharmacotherapy, sodium-glucose cotransporter 2 inhibition, and sodium-glucose cotransporter 2 inhibitors.

ORCID

Publications per year

2020–2025

Publications

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial

Bettina J. Kraus, Matthew R. Weir, George L. Bakris et al. · Kidney International · 2020 · 212 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

William T. Abraham, JoAnn Lindenfeld, Piotr Ponikowski et al. · European Heart Journal · 2020 · 212 citations

Medicine, Cardiology, Pharmacotherapy +16

Nerandomilast in Patients with Progressive Pulmonary Fibrosis

Toby M. Maher, Shervin Assassi, Arata Azuma et al. · New England Journal of Medicine · 2025 · 139 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled

João Pedro Ferreira, Faı̈ez Zannad, Javed Butler et al. · European Heart Journal · 2022 · 87 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials

Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku et al. · Diabetes Care · 2022 · 44 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

1–5 of 5